A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (BRIGHT 1012)
An Open-Label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Category & Conditions: Cancer
Medicine: DAURISMO TABLETS(GLASDEGIB)
ClinicalTrials.gov Identifier (NCT): NCT02367456
Protocol ID: B1371012
PrintDownloadOpen Plain Language Summary Result: Click here